

Addressing Scientific Challenges Associated with Emerging Regulatory Genetic Toxicology Guidance, Standard Testing Approaches and Genotoxic Impurities

September 9 -10, 2009
John M. Clayton Hall Conference Center
University of Delaware, Newark, DE

Scientific Meeting Program

Wednesday, September 9th, 2009

Breakfast and Registration

7:30 – 8:20 a.m.

Welcome and Introduction

8:20 – 8:30 a.m. Patricia Escobar, Boeringer-Ingelheim, GTA Chair

Keynote Presentation

8:30 – 9:30 a.m. Genotoxic impurities and risk: managing the unknown
Peter Kasper, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany

Symposium

9:30 a.m. – 12:15 p.m. ***Genotoxic Impurities and Genotoxic Metabolites of Pharmaceuticals: Case Studies***

Chairs: Krista Dobo and Timothy McGovern

Expert Panel: Peter Kasper, (BfArM), Joel Bercu (Eli Lilly), Timothy McGovern (SciLucent), David Jacobson-Kram (US-FDA CDER)

9:30 – 10:00 a.m. Towards developing an integrated approach to safety assessment of potentially genotoxic impurities, degradates and metabolites of pharmaceuticals
Sheila Galloway, Merck Research Laboratories

10:00 – 10:30 a.m. *Coffee Break*

10:30 – 10:45 a.m. Genotoxic impurities that are also metabolites: what's next?
Jim Harvey, Glaxo Smith Kline

10:45 – 11:00 a.m. Synthetic Intermediate that is also a Metabolite, Impurity and Degradate: What are the appropriate risk evaluation options?
Vijay Reddy, Merck Research Laboratories

11:00 – 11:15 a.m. Managing genotoxic impurities throughout development of a pharmaceutical: control strategies and case studies
Joel Bercu, Eli Lilly

11:15 – 11:30 a.m. Application of the staged TTC to a high dose drug intended for short-term use
Krista Dobo, Pfizer Global Research & Development

11:30 a.m. – 12:15 p.m. Expert Panel Discussion

Lunch and Awards Presentation

12:15 – 1:15 p.m.

Interactive Workshop

1:15 – 5:30 p.m. ***Positive In Vivo Micronucleus Findings: Mechanistic Studies to Assess Risk***

Chairs: Timothy Johnson & Magnus Evertson

Expert Panel: David Jacobson-Kram (US-FDA CDER), Maik Schuler (Pfizer Global R&D), Kevin Sweder (Bristol Myers Squibb), Hansjoerg Martus (Novartis), Ron Snyder (Schering Plough)

1:00 – 1:50 p.m. Assessing the potential risk of a positive in vivo micronucleus result
Timothy Johnson, Merck Research Laboratories

1:50 – 2:40 p.m. Strategy for better understanding in vivo micronucleus positives with kinase inhibitors
Maik Schuler, Pfizer Global Research & Development

2:40 - 3:30 p.m. Coffee Break

3:30 – 4:00 p.m. Kinase inhibitors and in vitro genetic toxicology assays
Kevin Sweder, Bristol Myers Squibb

4:00 – 4:30 p.m. Follow-up of positive in vivo genotoxicity results: Novartis experience
Hansjoerg Martus, Novartis

4:30– 5:30 p.m. Panel discussion

Poster Session

5:30 – 7:00 p.m.

Dinner (included in the 2-day registration fee)

7:00 – 8:30 p.m.

Thursday, September 10th, 2009

Breakfast and Registration

7:00 – 8:00 a.m.

Symposium

8:00 - 10:00 a.m. ***Advanced Technologies for Predictive Toxicology***

Chairs: Divi Rao, Pamela Heard and Ofelia Olivero

8:00 - 8:30 a.m. Overview- Introduction -Applicability/Feasibility of Rodent Imaging
Kathleen Gabrielson, Johns Hopkins University

8:30 - 9:00 a.m. Strategies to reduce NCE attrition due to mitochondrial toxicity- novel screening
methods
Sashikala Nadanaciva, Pfizer Global Research & Development

9:00 - 9:30 a.m. Developing biomarkers of immunotoxicity: flow cytometry and high-throughput
drug screening
Paurene Duramed, Genentech

9:30 - 10:00 AM Different approaches to the automation of in vitro micronucleus assay using image
analysis
Michael Homiski, Pfizer Global Research & Development

10:00 – 10:30 a.m. *Coffee Break*

Mini-Symposium

10:30 a.m. – 12:00 p.m. ***Genotoxic Modes of Action and Their Use in Cancer Risk Assessment***

Chairs: Nagu Keshava and Brinda Mahadevan

10:30 – 11:00 a.m. Introduction to genotoxic mode of action and its use in cancer risk assessment
Nagu Keshava, US-EPA

11:00 – 11:30 a.m. Understanding and differentiating the genotoxic mode of action using
toxicogenomics data
Michael Waters, Integrated Laboratory Systems

11:30 – 12:00 p.m. In vitro genotoxicity tests: concerns and considerations for sound science
Anuradha Mudipalli, US-EPA

Lunch and Business Meeting

12:00 – 1:00 p.m.

Interactive Workshop

1:00 – 4:00 p.m. ***Genetic Toxicology Testing Guidance – Results of Recent Validation Work / Revisiting ICH-S2R, OECD, Comet Collaboration and In Vitro MN Guidance***
Chairs: Sandy Weiner and Jiaqin Yao
Expert Panel: Sheila Galloway (Merck Research Laboratories), Laura Custer (Bristol Myers Squibb), David Kirkland (Consultant) and Dan Benz (US-FDA CDER)

1:00 – 1:25 p.m. An overview of the August 2009 IWGT workshops
David Kirkland, Consultant

1:25 – 1:50 p.m. Collaborative study on 15 compounds in the in vivo liver Comet assay integrated into 2- and 4-week studies
Sheila Galloway, Merck Research Laboratories

1:50 – 2:15 p.m. Aneugen detection in rat peripheral blood MN assay
Laura Custer, Bristol Myers Squibb

2:15 – 2:30 p.m. *Coffee Break*

2:30 – 2:55 p.m. The OECD in vitro MN guideline: Cytotoxicity issues
David Kirkland, Consultant

2:55 – 3:20 p.m. Transforming (Q)SAR computational toxicology from a research project to an integral part of the FDA/CDER regulatory process
Dan Benz, US-FDA CDER

3:20 – 4:00 p.m. Expert Panel Discussion

Closing Comments

4:00 p.m. Patricia Escobar, Boehringer-Ingelheim, GTA Chair
